Finance

Beta
Lists
OVID:NASDAQ
Ovid Therapeutics Inc
$2.55
+5.37%
(+0.13) 1D
$2.59
+1.57% (+0.040)
Pre-market
Closed: Jun 26, 4:00:01โ€ฏPM GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for OVID...
Open
$2.40
High
$2.60
Low
$2.39
Mkt. cap
475.93M
Avg. vol.
2.23M
Volume
4.39K
52-wk high
$3.10
52-wk low
$0.30
EPS
-$0.24
Beta
0.16
Shares outstanding
186.64M
No. of employees
23
Open
$2.40
High
$2.60
Low
$2.39
Mkt. cap
475.93M
Avg. vol.
2.23M
Volume
4.39K
52-wk high
$3.10
52-wk low
$0.30
EPS
-$0.24
Beta
0.16
Shares outstanding
186.64M
No. of employees
23
News stories
From sources across the web
About Ovid Therapeutics Inc
CEO-
Employees23
Founded2014
Headquarters-
SectorBiotechnology
Websiteovidrx.com
Analyst ratings
Based on 7 analysts giving stock ratings to OVID in the past 3 months
Strong buy
Buy
7
Hold
0
Sell
0
12-month forecast
Based on 7 Wall Street analysts offering 12 month price targets for OVID in the last 3 months.
Highest
Current $2.55
$7.00 (+174.51%)
Average
$5.60 (+119.61%)
Lowest
$4.00 (+56.86%)
Analyst
Recommendation
Action
Price target
Projected
Date
Ram Selvaraju
H.C. Wainwright
Buy
Reiterated
$4.00
+56.9%
06/08/2026
Francois Brisebois
LifeSci Capital
Buy
Maintained
$5.00
+96.1%
05/16/2026
Boobalan Pachaiyappan
Roth MKM
Buy
Reiterated
$7.00
+174.5%
05/14/2026
Unknown Analyst
B. Riley Securities
Buy
Reiterated
$5.00
+96.1%
05/13/2026
Laura Chico
Wedbush
Buy
Maintained
$7.00
+174.5%
05/13/2026
Ritu Baral
TD Cowen
Buy
Maintained
-
-
05/12/2026
Myles Minter
William Blair
Buy
Maintained
-
-
05/12/2026
Thomas Shrader
BTIG
Buy
Maintained
$4.00
+56.9%
03/26/2026
Madison Elsaadi
B. Riley Securities
Buy
Reiterated
$5.00
+96.1%
03/10/2026
Last report
May 12, 2026
Fiscal period
Q1 2026
EPS / Est. (USD)
-$0.12 / -$0.11
-13.21%miss
Revenue / Est. (USD)
- / 48.33K
Fiscal Q1 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in USD
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Revenue
6.27M
132.00K
718.00K
-
Cost of goods sold
-
-
-
-
Cost of revenue
-
-
-
-
Research and development expenses
6.46M
5.87M
6.59M
11.18M
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
4.88M
6.78M
6.42M
6.66M
Operating expense
11.34M
12.66M
13.01M
17.85M
Total operating expenses
11.34M
12.66M
13.01M
17.85M
Operating income
-5.07M
-12.52M
-12.29M
-17.85M
Other non operating income
5.00K
62.00K
57.00K
121.00K
EBT including unusual items
-4.68M
-12.16M
9.66M
-16.99M
EBT excluding unusual items
-4.68M
-12.16M
-11.39M
-16.99M
Income tax expense
-
-
-
-
Effective tax rate
-
-
-
-
Other operating expenses
-
-
-
-
Net income
-4.68M
-12.16M
9.66M
-16.99M
Net profit margin
-74.68%
-9,210.61%
1,345.82%
-
Earnings per share
-0.06
-0.17
0.06
-0.12
Interest and investment income
384.00K
303.00K
847.00K
737.00K
Interest expense
-
-
-
-
Net interest expenses
384.00K
303.00K
847.00K
737.00K
Depreciation and amortization charges
-
-
-
-
EBITDA
-4.97M
-12.51M
-12.28M
-17.81M
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer

Research

What's on your mind?
Give me an overview of OVID
Explore whatโ€™s possible
Deep Search
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer